About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

TERMINATEDPhase 4NCT00209417

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography

It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and ...

Lead sponsor: GE Healthcare•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

GE Healthcare

Collaborators

ABX CRO
Examination Management Services Inc.
Covance
Quintiles, Inc.
Averion International Corporation

GEHC has decided not to provide this detail

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with a combination of diabetes mellitus (type I or II) and renal impairment who are referred for a contrast-enhanced CT examination.

Exclusion Criteria

•Concurrent administration of potentially nephroprotective or nephrotoxic drugs is not permitted.
•Patients undergoing dialysis or kidney transplantation will not be included.

Related studies

RECRUITINGPhase 4

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

NCT06613854 · Type 2 Diabetes Mellitus (T2DM)

RECRUITINGPhase 1

Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes

NCT07535307 · Diabetes Mellitus

Evaluation of Children With Endocrine and Metabolic-Related Conditions

NCT02769975 · Adrenal Insufficiency, Growth Disorder, and more

RECRUITINGPhase 2

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

NCT07224321 · Type 1 Diabetes Mellitus

RECRUITINGPhase 4

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

NCT06862739 · Diabetes Mellitus, Type 2 DM

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 17, 2014Terms

Trial snapshot

StatusTERMINATED

PhasePHASE4

Enrollment656

Start dateJun 2005

Last updatedOct 17, 2014

Condition

Renal Insufficiency Diabetes Mellitus

Locations shown

GE Healthcare

Princeton, New Jersey

GE Healthcare

Amersham

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 17, 2014Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions